The current global poser as to whether immune-suppressing drugs should still be used to maintain adequate asthma control during the COVID-19 pandemic will no doubt be among the topical considerations to be addressed by noted South African allergologist, Dr Thulja Trikamjee, in a webinar presentation to be hosted by Aspen Pharmacare on Tuesday 26 May between 18h00 and 19h00.

A specialist paediatrician with a sub-specialty certificate in Paediatric Allergy/Immunology, a Diploma in Allergy, as well as the Union of European Medical Specialists Allergy and Immunology Certificate, Dr Trikamjee will be focusing on the treatment and management of asthma and allergic rhinitis in the current environment

Dr Trikamjee is at present a consultant at the University of Cape Town Lung Institute, a member of the Allergy Society of South Africa (ALLSA), a board member of the World Allergy Organization (WAO), and the only African elected board member of the European Academy of Allergy and Clinical Immunology (EAACI).

Her fellowship in Allergology was attained through the Discovery Foundation, who awarded her the Sub-Specialist Award in 2015, and she is also the recipient of the MSD ALLSA Research Award 2016 for her ongoing work on Aeroallergens in Dust.

Special interests and expertise include general paediatrics, critical care, asthma, food allergy, allergic rhinitis, drug and latex allergy, atopic dermatitis/eczema, immunotherapy, immunodeficiency, urticaria, angioedema, allergy diagnostics and testing.

*Registration details and more information can be accessed at

Ref: ZAR-NPR-05-20-00001 05/20